Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.